Loading company
Novo Nordisk A S
NVO · NYSE · ·
Next earnings: November 4, 2026
$38.31-1.0%Sep 29 close
- 1M
- -16.0%
- 6M
- +9.5%
- 1Y
- -28.6%
- 5Y
- -16.2%
Novo Nordisk A S is the 9th largest of 19 graded companies. Showing 5 of them, including NVO itself. 2 more are in this industry but have no grade yet, so they are left out rather than shown blank.
| Company | Grade | Market value | Revenue | Profit margin | Free cash flow | Price to earnings |
|---|---|---|---|---|---|---|
| ELI Lilly And CompanyLLY | A+ | $1.12T | $79.7B | 33.5% | $18.2B | 39.79 |
| Johnson & JohnsonJNJ | A+ | $644.8B | $97.9B | 21.5% | $22.2B | 31.04 |
| AbbVie Inc.ABBV | B | $465.2B | $64.4B | 9.8% | $18.2B | 74.37 |
| Merck & Co., Inc.MRK | A | $368.3B | $66.6B | 4.8% | $16.1B | 118.48 |
| Novo Nordisk A/SNVO | C+ | $170.4B | $50.1B | 35.3% | $9B | 10.93 |
14 more drug manufacturers general companies
Graded on the same five checks, from their own SEC filings.
A blank price-to-earnings means a loss, not a missing figure — the ratio has no meaning when there are no earnings to divide by, and printing a negative one would make the least profitable company look the cheapest.
Grades are trailing twelve months from each company’s own SEC filings, so they move only when a company files. Every column is computed by the same code that graded Novo Nordisk A S on the overview — nothing here comes from a data vendor’s own ratios.
Industry membership is not a judgement about how similar two businesses are. It groups companies by what they are classified as, which is a starting point for comparison rather than a claim that they compete.
NVO · NYSE · ·
Next earnings: November 4, 2026
$38.31-1.0%Sep 29 close